The Economic Burden of Atherosclerotic Cardiovascular Disease in Italy

被引:1
作者
Mennini, Francesco S. [1 ]
Scortichini, Matteo [1 ]
Colivicchi, Furio [2 ]
Maggioni, Aldo P. [3 ]
Sciattella, Paolo [1 ]
机构
[1] Univ Roma Tor Vergata, Fac Econ, Ctr Econ & Int Studies, Econ Evaluat & Hlth Technol Assessment, Via Columbia 2, I-00133 Rome, Italy
[2] San Filippo Neri Hosp, Div Cardiol, Rome, Italy
[3] ANMCO Res Ctr Heart Care Fdn, Florence, Italy
关键词
STATIN THERAPY; EZETIMIBE; RISK; ASSOCIATION; ADHERENCE; EFFICACY;
D O I
10.1007/s40261-024-01365-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundAtherosclerotic cardiovascular diseases remain the primary cause of mortality in Italy. Individuals with a history of acute coronary syndrome, peripheral arterial disease, and ischemic stroke/transient ischemic attack face an elevated risk of recurrent major adverse cardiovascular events, including mortality. The population aging, coupled with increasing risk factors such as diabetes mellitus and obesity, exacerbates the disease's economic impact.ObjectivesThis study aims to comprehensively assess the economic burden of atherosclerotic cardiovascular diseases in Italy, specifically focusing on direct healthcare costs.MethodsWe analyzed real-world data from administrative databases in the Marche region and Local Health Unit Umbria 2. The economic burden of patients discharged with acute coronary syndrome, peripheral arterial disease, and ischemic stroke/transient ischemic attack was evaluated, with a focus on direct costs associated with hospitalizations, drugs, and outpatient visits. Results were stratified by age, sex, comorbidities at baseline, and adherence to lipid-lowering therapy and antihypertensive agents.ResultsAnnually, nearly 350,000 patients were hospitalized for peripheral arterial disease, acute coronary syndrome, or ischemic stroke/transient ischemic attack. Direct health costs averaged <euro>7190 per patient over a 2-year follow-up, with hospitalizations accounting for nearly 70% of the total. Male patients incurred significantly higher costs (<euro>7467) than female patients (<euro>6625). Costs correlated positively with age and with the number of baseline comorbidities, with a range from <euro>5259 (0-1 comorbidities) to <euro>17,095 (4+ comorbidities). Costs were significantly lower in adherent subjects (<euro>6813) compared with non-adherent subjects (<euro>7757).ConclusionsThis study provides valuable insights into the economic implications of atherosclerotic cardiovascular diseases in Italy, emphasizing the necessity of a comprehensive approach to preventive measures, optimal medication adherence, and lifestyle modifications to mitigate its impact.
引用
收藏
页码:739 / 747
页数:9
相关论文
共 50 条
  • [41] Apolipoprotein B: An essential cholesterol metric for atherosclerotic cardiovascular disease
    Fischer, Kyle
    Kassem, Layla
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 (02) : 83 - 86
  • [42] Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea
    Kim, Siin
    Kim, Hyungtae
    Kim, Eunju
    Han, Sola
    Rane, Pratik P.
    Fox, Kathleen M.
    Zhao, Zhongyun
    Qian, Yi
    Suh, Hae Sun
    CLINICAL THERAPEUTICS, 2018, 40 (06) : 940 - 951
  • [43] A Clinical Perspective on Arsenic Exposure and Development of Atherosclerotic Cardiovascular Disease
    Kaur, Gurleen
    Desai, Karan P.
    Chang, Isabella Y.
    Newman, Jonathan D.
    Mathew, Roy O.
    Bangalore, Sripal
    Venditti, Ferdinand J.
    Sidhu, Mandeep S.
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 37 (06) : 1167 - 1174
  • [44] Periodontal disease, a risk factor for atherosclerotic cardiovascular disease
    Gheorghita Dorottya
    Eordegh Gabriella
    Nagy Ferenc
    Antal Mark
    ORVOSI HETILAP, 2019, 160 (11) : 419 - 425
  • [45] Burden of elevated lipoprotein(a) among patients with atherosclerotic cardiovascular disease: Evidence from a systematic literature review and feasibility assessment of meta-analysis
    Orfanos, Panagiotis
    Fonseca, Ana Filipa
    Hu, Xingdi
    Gautam, Raju
    Montgomery, Glenn
    Studer, Rachel
    Kaur, Japinder
    Saxena, Nehul
    Kaushik, Nitin
    PLOS ONE, 2023, 18 (11):
  • [46] Cardiovascular Disease in Patients with Diabetes: A Comparison of Professional Society Guidelines
    Salazar, Ilton M. Cubero
    Tibuakuu, Martin
    Blumenthal, Roger S.
    Sarkar, Sudipa
    CURRENT DIABETES REVIEWS, 2022, 18 (04)
  • [47] A systematic review of disparities in the medical management of atherosclerotic cardiovascular disease in females
    Simioni, Andrea
    Yi, Jeniann A.
    Imran, Rabbia
    Dua, Anahita
    SEMINARS IN VASCULAR SURGERY, 2023, 36 (04) : 517 - 530
  • [48] Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease?
    Poredos, Pavel
    Jezovnik, Mateja Kaja
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (07) : 14477 - 14489
  • [49] Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly
    Lucchi, Tiziano
    MINERVA MEDICA, 2021, 112 (06) : 804 - 816
  • [50] Strategies to alter the trajectory of atherosclerotic cardiovascular disease
    Packard, Chris J.
    CURRENT OPINION IN LIPIDOLOGY, 2019, 30 (06) : 438 - 445